ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Translational Session

The Revolution Is Here: New Treatments for Diabetes and Kidney Diseases, Including the Barry M. Brenner, MD, Endowed Lectureship

November 07, 2019 | 10:30 AM - 12:30 PM

Location: Ballroom C, Walter E. Washington Convention Center

Session Description

Experts in the fields of nephrology and diabetology review emerging data about underlying biological mechanisms of complications and key clinical trials of newer glucose-lowering agents. The session provides the most current evidence and recommendations for preventing the kidney and cardiovascular complications of both type 1 and type 2 diabetes. The educational content is designed for an audience of both clinicians and scientists.

ASN gratefully acknowledges Monarch Pharmaceuticals for support of the Barry M. Brenner, MD, Endowed Lectureship.

ASN thanks the American Diabetes Association for assistance with this session.

Support is provided by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Learning Objective(s)

  • Integrate structural assessment to advance knowledge and treatment of diabetic kidney disease (DKD)
  • Compare the key clinical trials of newer glucose-lowering agents that investigated CVD and DKD outcomes in diabetes
  • Describe application of newer glucose-lowering agents to individualize treatments

Learning Pathway(s)

  • Diabetes and Metabolism
  • Chronic Kidney Disease

Moderators

  • Adeera Levin, MD
  • Susanne B. Nicholas, MD, PhD, MPH

Presentations

  • Diabetic Kidney Disease: Structural-Functional Relationships and the Possibilities of Cure - The Barry M. Brenner, MD, Endowed Lectureship
    10:30 AM - 11:00 AM
    Michael Mauer, MD 
  • Kidney and Cardiovascular Effects of SGLT-2 Inhibitors
    11:00 AM - 11:30 AM
    Christoph Wanner, MD
  • Kidney and Cardiovascular Effects of Glucagon-Like-Peptide-1 Receptor Agonists
    11:30 AM - 12:00 PM
    Mark E. Cooper, MBBS, PhD, FASN 
  • SGLT2 Inhibitors and GLP-1 Receptor Agonists: Which Medications for Which Patients?
    12:00 PM - 12:30 PM
    David Cherney, MD, PhD